Vanberra Signal
Free trial

Evariste

Curated by Signal

AI-based drug discovery platform to target synthetic lethal pathways in oncology

Health Technologyevariste.com

Overview

AI-based drug discovery platform to target synthetic lethal pathways in oncology. The company uses Frobenius AI drug discovery platform that integrates multi-modal data to identify novel druggable targets and biomarkers, significantly increasing the likelihood of clinical success. The company's pipeline includes inhibitors for validated synthetic lethal targets, such as PKMYT1 and VRK1, for treating various cancers.

Key facts

Founded
2017
Headquarters
London, United Kingdom
Stage
Sign up to view
Industry
Health Technology

Business model

6 products and services
Sign up to view

Contact

Primary office
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

  • PharmaQue

    Provider of Q & A and discussion platform for pharmacy professionals

    Health TechnologyLondon, United Kingdom

  • Axiom Devices

    Provider of neuromonitoring devices for neuro and spine surgery

    Health TechnologyBishop's Stortford, United Kingdom

  • MedExpress

    MedExpress is an online doctor & pharmacy based in the UK

    Health TechnologyLondon, United Kingdom

About Evariste

What does Evariste do?

AI-based drug discovery platform to target synthetic lethal pathways in oncology.

Where is Evariste headquartered?

Evariste is headquartered in London, United Kingdom.

When was Evariste founded?

Evariste was founded in 2017.

Which sector is Evariste in?

Evariste operates in Health Technology.

Who are Evariste's competitors?

Companies similar to Evariste include PharmaQue, Axiom Devices, and MedExpress.